Cargando…

Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial

The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is poorly understood and therapeutic strategies are lacking. This study aimed to identify plasma proteins with pathophysiological relevance in HFpEF and with respect to spironolactone-induced effects. We assessed 92 biomar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schnelle, Moritz, Leha, Andreas, Eidizadeh, Abass, Fuhlrott, Katharina, Trippel, Tobias D., Hashemi, Djawid, Toischer, Karl, Wachter, Rolf, Herrmann-Lingen, Christoph, Hasenfuß, Gerd, Pieske, Burkert, Binder, Lutz, Edelmann, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535031/ https://www.ncbi.nlm.nih.gov/pubmed/34685778 http://dx.doi.org/10.3390/cells10102796

Ejemplares similares

Economic impact of heart failure with preserved ejection fraction: insights from the ALDO‐DHF trial
por: Hashemi, Djawid, et al.
Publicado: (2020)

The diagnostic and prognostic value of galectin‐3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST‐CHF study
por: Trippel, Tobias Daniel, et al.
Publicado: (2021)

Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex‐DHF pilot study
por: Trippel, Tobias Daniel, et al.
Publicado: (2016)

Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST‐CHF study
por: Eidizadeh, Abass, et al.
Publicado: (2022)

ALDO-DHF & Paramount
por: ElGuindy, Ahmed M
Publicado: (2013)

Influence of baseline parameters on one‐year physical, mental, and health‐related quality of life in patients with heart failure and preserved ejection fraction
por: Fitz, Judith, et al.
Publicado: (2021)

Longitudinal association between N-terminal B-type natriuretic peptide, anxiety and social support in patients with HFpEF: results from the multicentre randomized controlled Aldo-DHF trial
por: Wilke, Marieke R., et al.
Publicado: (2023)

Evaluation of the HFA‐PEFF Score: results from the prospective DIAST‐CHF cohort
por: Hashemi, Djawid, et al.
Publicado: (2022)

The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction
por: Stahrenberg, Raoul, et al.
Publicado: (2010)

Outcome assessment using estimation of left ventricular filling pressure in asymptomatic patients at risk for heart failure with preserved ejection fraction
por: Bobenko, Anna, et al.
Publicado: (2020)

Saturated Fatty Acid Blood Levels and Cardiometabolic Phenotype in Patients with HFpEF: A Secondary Analysis of the Aldo-DHF Trial
por: Lechner, Katharina, et al.
Publicado: (2022)

Amount or intensity? Potential targets of exercise interventions in patients with heart failure with preserved ejection fraction
por: Bobenko, Anna, et al.
Publicado: (2017)

Determinants of submaximal exercise capacity in patients at risk for heart failure with preserved ejection fraction—results from the DIAST‐CHF study
por: Stahrenberg, Raoul, et al.
Publicado: (2015)

Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction
por: Nolte, Kathleen, et al.
Publicado: (2019)

Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trial
por: Lechner, Katharina, et al.
Publicado: (2021)

Trans-fatty acid blood levels of industrial but not natural origin are associated with cardiovascular risk factors in patients with HFpEF: a secondary analysis of the Aldo-DHF trial
por: Lechner, Katharina, et al.
Publicado: (2023)

Inconsistent Findings of Cardiac Troponin T and I in Clinical Routine Diagnostics: Factors of Influence
por: Eidizadeh, Abass, et al.
Publicado: (2021)

Comparison of a novel automated DiaSys procalcitonin immunoassay with four different BRAHMS-partnered immunoassays
por: Eidizadeh, Abass, et al.
Publicado: (2022)

A short form of the General Self-Efficacy Scale (GSE-6): Development, psychometric properties and validity in an intercultural non-clinical sample and a sample of patients at risk for heart failure
por: Romppel, Matthias, et al.
Publicado: (2013)

Natriuretic peptides for the detection of paroxysmal atrial fibrillation
por: Seegers, Joachim, et al.
Publicado: (2015)

Syncopes and clinical outcome in heart failure: results from prospective clinical study data in Germany
por: Hashemi, Djawid, et al.
Publicado: (2020)

Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction
por: Edelmann, Frank, et al.
Publicado: (2011)

Association of glucose metabolism with diastolic function along the diabetic continuum
por: Stahrenberg, R., et al.
Publicado: (2010)

Left atrial function and maximal exercise capacity in heart failure with preserved and mid‐range ejection fraction
por: Maffeis, Caterina, et al.
Publicado: (2020)

Elevated Plasma C-Terminal Endothelin-1 Precursor Fragment Concentrations Are Associated with Less Anxiety in Patients with Cardiovascular Risk Factors. Results from the Observational DIAST-CHF Study
por: Meyer, Thomas, et al.
Publicado: (2015)

Heart failure awareness survey in Germany: general knowledge on heart failure remains poor
por: Zelenak, Christine, et al.
Publicado: (2017)

Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trials
por: Kresoja, Karl-Patrik, et al.
Publicado: (2023)

Multilayer myocardial strain improves the diagnosis of heart failure with preserved ejection fraction
por: Tanacli, Radu, et al.
Publicado: (2020)

Erratum to: Association of glucose metabolism with diastolic function along the diabetic continuum
por: Stahrenberg, R., et al.
Publicado: (2011)

Higher galectin-3 levels are independently associated with lower anxiety in patients with risk factors for heart failure
por: Sadlonova, Monika, et al.
Publicado: (2020)

Single center experience of CMR findings after COVID-19 and after COVID-19-vaccination
por: Doeblin, Patrick, et al.
Publicado: (2022)

Reduced functional capacity is associated with the proportion of impaired myocardial deformation assessed in heart failure patients by CMR
por: Hashemi, Djawid, et al.
Publicado: (2023)

CMR detects decreased myocardial deformation in asymptomatic patients at risk for heart failure
por: Hashemi, Djawid, et al.
Publicado: (2023)

Range Variability in CMR Feature Tracking Multilayer Strain across Different Stages of Heart Failure
por: Tanacli, Radu, et al.
Publicado: (2019)

Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care
por: Koschack, Janka, et al.
Publicado: (2008)

Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Benini, Annachiara, et al.
Publicado: (2022)

NT‐proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials
por: Werhahn, Stefanie M., et al.
Publicado: (2021)

Clinical Manifestations and Management of Dengue/DHF/DSS
por: Kalayanarooj, Siripen
Publicado: (2011)

Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure
por: Wachter, Rolf, et al.
Publicado: (2009)

Natriuretic peptides in the detection of preclinical diastolic or systolic dysfunction
por: Luers, Claus, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_4tf4q52huk5c5suf0dfrj2atmp